Abstract: A tissue-targeting complex is described that comprises at least one targeting element [A-L-Q+-Alk B-] in which A is an amino-containing anchor element, L a linker, Q+ a quaternary ammonium group, B- an ophthalmologically acceptable counterion, and Alk an alkyl chain having 4 to 12 carbon atoms; at least one chromophore, and optionally a carrier molecule.

Abstract: A syringe device and a syringe system with a syringe device provides an ergonomic syringe device which enables safe operation and safe injection by using a pen-like syringe device having a drive housing, a syringe receptacle for receiving a syringe having a syringe body and a plunger guided therein, and a manually operable push button for activating an electrical delivery unit. The drive housing has a pressure supply unit for pneumatically actuating the plunger and a coupling connection for connection to an external supply unit. The pressure supply unit includes a drive channel which can be connected to the plunger of an inserted syringe. The syringe device has a vent channel connected to the drive channel and via an opening to the environment, the opening being closable by a finger when the push button is actuated.

Abstract: A pen-like syringe system includes: a syringe holder for receiving a syringe having a syringe barrel and a plunger guided for movement in the barrel; and a drive housing connected to the syringe holder. To provide an ergonomic syringe system which allows advantageous operation of the system and guarantees safe and focused injection or drawing of a substance the drive housing includes an electric delivery device operated by an integrated power supply for applying pneumatic pressure or negative pressure to the plunger, with the delivery device connected via a drive channel to the plunger and actuatable by a button arranged on the syringe system; and the pen-like syringe system has a vent duct with a first end, which is connected to the drive channel, and a second end, which is connected to the surroundings via an opening, with the opening closable by pressing the button.

Abstract: The invention relates to modified polysaccharide ethers having a weight-averaged molecular weight of 40,000 to 500,000 g/mole, zero shear viscosity of more than 10 Pa·s, and pseudo-plasticity of more than 20. These modified polysaccharide ethers are obtainable by reacting cellulose-based polysaccharide ether(s) with at least one mesogenic modification agent or modified polysaccharide ethers, obtainable by reacting polysaccharide ether(s) selected from hydroxypropylmethyl cellulose (HPMC), hydroxyethylmethyl cellulose (HEMC), methyl cellulose, and cellulose ethers with methyl and/or ethyl and/or propyl groups and mixtures thereof, with at least one mesogenic modification agent. These substances can be used to produce gel-like to stable aqueous preparations having viscoelastic flow properties, which are suited for use in the human body, particularly within the scope of ophthalmologic procedures.

Abstract: The invention relates to modified polysaccharide ethers having a weight-averaged molecular weight of 40000 to 50000 g/mole, zero shear viscosity of more than 10 Pas, and pseudoplasticity of more than 20, obtainable by reacting cellulose-based polysaccharide ether(s) with at least one mesogenic modification agent or modified polysaccharide ethers, obtainable by reacting polysaccharide ether(s) selected from the group consisting of hydroxypropylmethyl cellulose (HPMC), hydroxyethylmethyl cellulose (HEMC), methyl cellulose, and cellulose ethers with methyl and/or ethyl and/or propyl groups and mixtures thereof, with at least one mesogenic modification agent. Said substances can be used to produce gel-like to stable aqueous preparations having viscoelastic flow properties, which are suited for use in the human body, particularly within the scope of ophthalmologic procedures.

Abstract: The invention includes a method for the passivation of the surface of an intraocular lens, wherein the surface includes Brönsted sites. The intraocular lens is dipped into a solution of a fluoroalkyl silane having the general formula: Rf—(CH2)n—Si—(O—R)3. The residue R is selected from the group of H, CH3, C2H5 and C3H7 and the fluoroalkyl residue Rf is selected from the series CF3(CF2)m, with m=3 to 11 and n=0 to 4. The Brönsted sites on the surface are thereby deactivated by formation of Si—Q—bonds.

Abstract: The invention relates to a plastically deformable implant for inserting into bodily orifices of the human or animal body. Implants of this type are used, for example, in ophthalmology, in particular, as vitreous body or lens replacements and in dentistry, for example, for filling extraction cavities in jaw-bones. Known implants, however, are not suitable for long-term use. The invention aims to provide a deformable plastic implant which also has a long-term application. This is achieved by the fact that the implant consists of a gel which is not sealed, containing fluorocarbon and which is directly introduced into the natural, or artificially created bodily orifice.

Abstract: The invention relates to the utilization of a highly fluorinated oligomeric alkane as a therapeutic agent in ophthalmology, the alkane having the general formula [—RF(CH2)nCR1—CR2—]x, wherein RF is a linear or branched perfluorinated alkyl chain C2F5 to C12F23, R1 and R2 are independently selected from the group consisting of H, CH3, C2H5 and C3H7, n is selected from the numbers 0, 1 and 2, and x is a number between 2 and 6, with a molar mass of at least 750. According to the invention, a pharmacological agent is provided that is used in ophthalmology and that causes little or no damage to the retina even when used over a long period.

Abstract: A tear replacement solution that contains at least one water-soluble fluorosurfactant, water and a non-polar component, preferably in gel form, and a method for the external treatment for the eye of an mammal by applying the tear replacement solution to the eye, preferably by placing in the conjunctival sac.

Abstract: The invention relates to a plastically deformable implant for inserting into bodily orifices of the human or animal body. Implants of this type are used, for example, in ophthalmology, in particular, as vitreous body or lens replacements and in dentistry, for example, for filling extraction cavities in jaw-bones. Known implants, however, are not suitable for long-term use. The invention aims to provide a deformable plastic implant which also has a long-term application. This is achieved by the fact that the implant consists of a gel which is not sealed, containing fluorocarbon and which is directly introduced into the natural, or artificially created bodily orifice.

Abstract: The invention relates to a plastically deformable implant for inserting into bodily orifices of the human or animal body. Implants of this type are used, for example, in ophthalmology, in particular, as vitreous body or lens replacements and in dentistry, for example, for filling extraction cavities in jaw-bones. Known implants, however, are not suitable for long-term use. The invention aims to provide a deformable plastic implant which also has a long-term application. This is achieved by the fact that the implant consists of a gel which is not sealed, containing fluorocarbon and which is directly introduced into the natural, or artificially created bodily orifice.

Abstract: The invention relates to a method for the passivation of the surface of an intraocular lens, the surface of which comprises reactive Brönsted sites. Conventional methods of the above type create changes on the original material and exhibit undesired interactions with medical adjuncts. The aim of the invention is to describe a method in which the intraocular lens is passivated and coated in an advantageous manner and only minimal changes are brought about on the original material. Said aim is achieved, whereby the intraocular lens is dipped in a solution of a fluoroalkylsilane of general formula RF—(CH2)n—Si—(O—R)3, where R═H, CH3, C2H5, or C3H7 and the fluoroalkyl group RF═CF3 (CF2)m where m=3 to 11 and n=0 to 4, whereby the Brönsted centres on the surface are deactivated by formation of Si—O bonds.

Abstract: The present invention concerns fluorocarbons for use in ophthalmology. Fluorocarbons disclosed in the prior art can only be left in the eye for a limited period of time because they cause damage to the retina or intraocular structure. The present invention provides an oxygen-fluorocarbon mixture having a dissolved oxygen content of less than 6% by volume, which can be used as an ophthalmological agent for longer periods of time than conventional fluorocarbons, with little or no damage to the retina or intraocular structures. The invention also provides a process for preparing the oxygen-fluorocarbon mixture. In one embodiment, up to 20% by volume of a second gas, such as carbon dioxide or nitric oxide, is combined with the oxygen-fluorocarbon mixtures.

Abstract: The present invention concerns fluorocarbons for use in ophthalmology. Fluorocarbons disclosed in the prior art can only be left in the eye for a limited period of time because they cause damage to the retina or intraocular structure. The present invention provides an oxygen-fluorocarbon mixture having a dissolved oxygen content of less than 6% by volume, which can be used as an ophthalmological agent for longer periods of time than conventional fluorocarbons, with little or no damage to the retina or intraocular structures. The invention also provides a process for preparing the oxygen-fluorocarbon mixture. In one embodiment, up to 20% by volume of a second gas, such as carbon dioxide or nitric oxide, is combined with the oxygen-fluorocarbon mixtures.

Abstract: The invention concerns a partially fluorinated alkane with the general formula RF[CF2—CH2]RH, wherein RH is a substituent of the general formula CnHx selected from the group consisting of n-alkyl, sec-alkyl, tert-alkyl and cycloalkyl; RF is a substituent of the general formula CmFx selected from the group consisting of the perfluoro-n-alkyl, perfluoro-sec-alkyl, perfluoro-tert-alkyl, and perfluorocycloalkyls, with the proviso that only one of RF and RH can be linear, and that n>3, the sum of n+m<18 and that only either RH or RF are an n-alkyl or perfluorinated n-alkyl. These partially fluorinated alkanes find use as solvents, especially in medical applications where the properties of hydrocarbon solvents are not acceptable, in implants, and as an oxygen carrying blood substitute.